Evidence-based recommendations on rituximab for treating follicular lymphoma in adults.
This guidance replaces NICE technology appraisal guidance 110.
The recommendations also apply to rituximab biosimilar products that have a marketing authorisation allowing the use of the biosimilar for the same indication.
We reviewed the evidence in August 2014. We found nothing new that affects the recommendations in this guidance.
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.